Literature DB >> 11083750

Changes in myocardial cytoskeletal intermediate filaments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans.

S Di Somma1, M Marotta, G Salvatore, G Cudemo, G Cuda, F De Vivo, M P Di Benedetto, F Ciaramella, G Caputo, O de Divitiis.   

Abstract

AIM: To investigate in vivo the intermediate cytoskeletal filaments desmin and vimentin in myocardial tissues from patients with dilated cardiomyopathy, and to determine whether alterations in these proteins are associated with impaired contractility.
METHODS: Endomyocardial biopsies were performed in 12 patients with dilated cardiomyopathy and in 12 controls (six women with breast cancer before anthracycline chemotherapy and six male donors for heart transplantation). Biopsy specimens were analysed by light microscopy and immunochemistry (desmin, vimentin). Myocyte contractile protein function was evaluated by the actin-myosin in vitro motility assay. Left ventricular ejection fraction was assessed by echocardiography and radionuclide ventriculography.
RESULTS: Patients with dilated cardiomyopathy had a greater cardiomyocyte diameter than controls (p < 0.01). The increase in cell size was associated with a reduction in contractile function, as assessed by actin-myosin motility (r = -0.643; p < 0.01). Quantitative immunochemistry showed increased desmin and vimentin contents (p < 0.01), and the desmin distribution was disturbed in cardiomyopathy. There was a linear relation between desmin distribution and actin-myosin sliding in vitro (r = 0.853; p < 0.01) and an inverse correlation between desmin content and ejection fraction (r = -0.773; p < 0.02). Negative correlations were also found between myocardial vimentin content and the actin-myosin sliding rate (r = -0.74; p < 0.02) and left ventricular ejection fraction (r = -0.68; p < 0.01).
CONCLUSIONS: Compared with normal individuals, the myocardial tissue of patients with dilated cardiomyopathy shows alterations of cytoskeletal intermediate filament distribution and content associated with reduced myocyte contraction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083750      PMCID: PMC1729530          DOI: 10.1136/heart.84.6.659

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  39 in total

Review 1.  A user's guide for avoiding errors in absorbance image cytometry: a review with original experimental observations.

Authors:  P Chieco; A Jonker; C Melchiorri; G Vanni; C J Van Noorden
Journal:  Histochem J       Date:  1994-01

Review 2.  Cellular mechanisms of cardiac failure in the infarcted heart.

Authors:  P Anversa; S Di Somma; G Bianchi; B Li; J Kajstura; W Cheng; E H Sonnenblick; G Olivetti; P Li
Journal:  Cardiologia       Date:  1995-12

Review 3.  Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure.

Authors:  V M Figueredo; S A Camacho
Journal:  Curr Opin Cardiol       Date:  1995-05       Impact factor: 2.161

Review 4.  Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure.

Authors:  M R Bristow; E M Gilbert
Journal:  Eur Heart J       Date:  1995-07       Impact factor: 29.983

5.  Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. II. Tissue composition, capillary growth, and sarcoplasmic alterations.

Authors:  G Olivetti; P Anversa; A V Loud
Journal:  Circ Res       Date:  1980-04       Impact factor: 17.367

6.  Desmin mutation responsible for idiopathic dilated cardiomyopathy.

Authors:  D Li; T Tapscoft; O Gonzalez; P E Burch; M A Quiñones; W A Zoghbi; R Hill; L L Bachinski; D L Mann; R Roberts
Journal:  Circulation       Date:  1999-08-03       Impact factor: 29.690

7.  The role of the cytoskeleton in left ventricular pressure overload hypertrophy and failure.

Authors:  J F Collins; C Pawloski-Dahm; M G Davis; N Ball; G W Dorn; R A Walsh
Journal:  J Mol Cell Cardiol       Date:  1996-07       Impact factor: 5.000

8.  Functional significance of myocellular hypertrophy in dilated cardiomyopathy: histomorphometric analysis on 40 endomyocardial biopsies.

Authors:  P Gallo; G d'Amati; F Pelliccia; P Bernucci; C Cianfrocca; B Marino
Journal:  Am J Cardiovasc Pathol       Date:  1995

9.  Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy.

Authors:  G Cuda; L Fananapazir; W S Zhu; J R Sellers; N D Epstein
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

10.  Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy.

Authors:  J Schaper; R Froede; S Hein; A Buck; H Hashizume; B Speiser; A Friedl; N Bleese
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more
  19 in total

1.  Transforming growth factor-beta(1) expression in dilated cardiomyopathy.

Authors:  J E Sanderson; K B Lai; I O Shum; S Wei; L T Chow
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

2.  Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study.

Authors:  G Hetet; B Grandchamp; C Bouchier; V Nicaud; L Tiret; G Roizès; M Desnos; K Schwartz; R Dorent; M Komajda
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Contrast enhanced magnetic resonance angiography and pulmonary venous anomalies.

Authors:  F Godart; S Willoteaux; C Rey; B Cocheteux; C Francart; J P Beregi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

4.  Effects of cardiac resynchronisation on maximal and submaximal exercise performance in advanced heart failure patients with conduction abnormality.

Authors:  D Birnie; L P Soucie; S Smith; A S Tang
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

5.  Reciprocal increase of circulating interleukin-10 and interleukin-6 in patients with acute myocardial infarction.

Authors:  N Kotajima; T Kimura; T Kanda; A Kuwabara; Y Fukumura; M Murakami; I Kobayashi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

6.  Percutaneous aortic valve replacement: will we get there?

Authors:  Y Boudjemline; P Bonhoeffer
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

7.  Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin.

Authors:  S Verma; A S Dumont; A Maitland
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

8.  Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function.

Authors:  Mustafa I Ahmed; Jason L Guichard; Rajasekaran Namakkal Soorappan; Shama Ahmad; Nithya Mariappan; Silvio Litovsky; Himanshu Gupta; Steven G Lloyd; Thomas S Denney; Pamela Cox Powell; Inmaculada Aban; James Collawn; James E Davies; David C McGiffin; Louis J Dell'Italia
Journal:  J Thorac Cardiovasc Surg       Date:  2016-06-25       Impact factor: 5.209

9.  Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Alexander Staudt; Christiane Trimpert; Michel Noutsias; Uwe Kühl; Matthias Pauschinger; Heinz-Peter Schultheiss; Markus Grube; Michael Böhm; Gert Baumann; Uwe Völker; Heyo K Kroemer; Stephan B Felix
Journal:  J Mol Med (Berl)       Date:  2007-10-09       Impact factor: 4.599

Review 10.  Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems.

Authors:  Mitja Lainscak; Stefan D Anker
Journal:  Herz       Date:  2009-03       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.